| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.03 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | 0.14 | 0.03 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.03 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.03 |
| mRNA | lapatinib | FIMM | pan-cancer | AAC | 0.34 | 0.04 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.081 | 0.04 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.35 | 0.04 |